Corbadrine, sold under the brand name Neo-Cobefrine and also known as levonordefrin and ñ-methylnorepinephrine, is a catecholamine sympathomimetic used as a topical nasal decongestant and vasoconstrictor in dentistry in the United States. It is usually used in a pre-mixed solution with local anesthetics, such as mepivacaine.
The drug acts as a non-selective agonist of the ñ<sub>1</sub>-, ñ<sub>2</sub>-, and ò-adrenergic receptors. It is said to have preferential activity at the ñ<sub>2</sub>-adrenergic receptor.
Corbadrine is also a metabolite of the antihypertensive drug methyldopa and plays a role in its pharmacology and effects.
Corbadrine is metabolized primarily by catechol O-methyltransferase (COMT).
Corbadrine, also known as 3,4,ò-trihydroxy-ñ-methylphenethylamine or as 3,4,ò-trihydroxyamphetamine, as well as ñ-methylnorepinephrine or (âÂÂ)-3,4-dihydroxynorephedrine, is a substituted phenethylamine and amphetamine derivative.
Analogues of corbadrine include ñ-methyldopamine, dioxifedrine (3,4-dihydroxyephedrine; ñ-methylepinephrine), dioxethedrin (3,4-dihydroxy-N-ethylnorephedrine; ñ-methyl-N-ethylnorepinephrine), and hydroxyamphetamine (4-hydroxyamphetamine; ñ-methyltyramine).
Corbadrine is the generic name of the drug and its . It is also known as levonordefrin, which is its . Synonyms of corbadrine include ñ-methylnorepinephrine and (âÂÂ)-3,4-dihydroxynorephedrine. The drug has been sold under the brand name Neo-Cobefrine.